<DOC>
	<DOCNO>NCT02026973</DOCNO>
	<brief_summary>Endogenous estrogen maintain growth hormone ( GH ) secretion postmenopausal woman potentiate endogenous GH-releasing hormone ( GHRH ) drive restrain somatostatin inhibition GH release .</brief_summary>
	<brief_title>Impact Endogenous E2 SSI GH Rebound</brief_title>
	<detailed_description>Systemic concentration testosterone ( Te ) , estradiol ( E2 ) , GH , IGF-I IGFBP-3 decline healthy age individual ( 1-3 ) . Sex-steroid deprivation accentuate GH IGF-I depletion , since Te E2 stimulate GH IGF-I production older adult , hypogonadal patient age , patient undergo gender reassignment ( 1,2,4 ) . Tamoxifen block effect Te , suggest involvement E2 GH 's stimulation men ( 5 ) . E2 also stimulate GH secretion woman , putatively via nuclear estrogen receptor ( ER-alpha ) ( 1,2,6,7 ) . Because Te , E2 GH fall menopause , Te convert E2 aromatization body ( 8-10 ) , postulate diminish Te concentration , Teâ†’E2 concentration low E2 mediate low GH output old woman . What remain unknown whether low E2 level postmenopausal woman retain GH-stimulating effect . To test notion would require blocking : ( ) aromatase-enzyme activity , mediate E2 synthesis Te , and/or ( ii ) estrogen receptor-alpha , transduce E2 's stimulation GH axis .</detailed_description>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Inclusion : 1 . 60 healthy postmenopausal woman ( age 55 80 ) ; 2 . BMI 1830 kg/m2 3 . Community dwell ; voluntarily consent Exclusion : 1 . Recent use psychotropic neuroactive drug ( within five biological halflives ) ; 2 . Obesity ( outside weight range ) ; 3 . Laboratory test result deem physician acceptable , cholesterol &gt; 250 , triglyceride &gt; 300 , BUN &gt; 30 creatinine &gt; 1.5 mg/dL , liver function test exceed twice upper limit normal , electrolyte abnormality , anemia ; 4 . Drug alcohol abuse , psychosis , depression , mania severe anxiety ; 5 . Systemic inflammatory disease ; 6 . Endocrinopathy , primary thyroidal failure receive replacement ; 7 . Nightshift work recent transmeridian travel ( exceed 3 time zone within 7 day CRU admission ) ; 8 . Acute weight change ( loss gain &gt; 2 kg 6 week ) ; 9 . Systemic illness 10 . Unwillingness provide write informed consent . 11 . Allergy anastrozole fulvestrant ( treatment drug ) . 12 . History suspicion breast cancer . 13 . History carcinoma ( exclude localize basal cell carcinoma remove surgically treat recurrence ) . 14 . History thrombotic arterial disease ( stroke , TIA , MI , angina ) deepvein thrombophlebitis . 15 . History CHF , cardiac arrhythmia , congenital QT prolongation , medication use treat cardiac arrhythmia . 16 . Premenopausal status determine screen hormone measurement .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>